References
- Bladé J, Kyle R A, Greipp P R. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345–351
- Damaj G, Mohty M, Vey N, Dincan E, Bouabdallah R, Faucher C, et al. Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol 2004; 73: 402–406
- Bladé J, Perales M, Rosiñol L, Montserrat T, Silvia M, Jordi E, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 13: 422–425
- Rosiñol L, Cibeira M T, Bladé J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832–836
- Biagi J J, Mileshkin L, Grigg A P, Westerman D W, Prince H M. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001; 42: 683–687
- González-Porras J R, González M, García-Sanz R, San Miguel J F. Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. Br J Haematol 2002; 119: 883–884
- Dytfeld D, Matuszak M, Lewandowski K, Komarnicki M. Bortezomib in combination with thalidomide and dexamethasone – a successful treatment regimen in refractory extramedullary multiple myeloma. Ann Hematol 2008; 87: 253–254
- Ali R, Ozkalemkas F, Ozkan A, Ozkocaman V, Ozcelik T, Ozan U, et al. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon. Leuk Res 2007; 31: 1153–1155
- Rosiñol L, Cibeira M T, Uriburu C, Yantorno S, Salamero O, Bladé J, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006; 76: 405–408
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757
- Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123
- Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
- Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
- Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826–831
- Morgan G J, Davies F E, Owen R G, Rawstron A C, Bell S E, Cocks K, et al. Thalidomide combinations improve response rates; results from the MRC IX study. Blood (ASH Annual Meeting Abstracts) 2007; 110: 3593
- Wu P, Davies F E, Horton C, Jenner M W, Krishnan B, Alvares C L, et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide–vincristine–doxorubicin–methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma 2006; 47: 2335–2338